Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 1.00 |
| ▸ | PSMA7 | O14818 | 2/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 2/20 | 1.00 |
| ▸ | PSMA1 | P25786 | 2/20 | 1.00 |
| ▸ | PSMA2 | P25787 | 2/20 | 1.00 |
| ▸ | PSMA3 | P25788 | 2/20 | 1.00 |
| ▸ | PSMA4 | P25789 | 2/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 2/20 | 1.00 |
| ▸ | PSMB9 | P28065 | 2/20 | 1.00 |
| ▸ | PSMA5 | P28066 | 2/20 | 1.00 |
| ▸ | PSMB4 | P28070 | 2/20 | 1.00 |
| ▸ | PSMB6 | P28072 | 2/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 2/20 | 1.00 |
| ▸ | PSMB10 | P40306 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piplartine SCHEMBL173092 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| (Z)-Piplartine SCHEMBL30013548 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL12675623 | 0.93 | ALDH1A1 (0.87) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL15422559 | 0.93 | ALDH1A1 (0.87) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL15422557 | 0.93 | ALDH1A1 (0.87) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL173090 | 0.91 | ALDH1A1 (0.83) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL25283508 | 0.90 | ALDH1A1 (0.82) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL173088 | 0.90 | ALDH1A1 (0.82) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL25283503 | 0.89 | ALDH1A1 (0.80) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL19295194 | 0.89 | ALDH1A1 (0.80) | ALDH1A1TP53HSD17B10MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968755-B2 | Topical base and active agent-containing compositions, and methods for improving and treating skin | SCHLESSINGER JOEL (US) | 2015-03-03 | — | — | US | claimed |
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | SCHLESSINGER JOEL (US) | 2013-07-11 | — | — | US | claimed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-12070465-B2 | Compositions and methods for the prevention and treatment of hearing loss | TING THERAPEUTICS LLC (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024033372-A1 | ANTIVIRAL COMPOUND | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2024-02-15 | — | — | WO | disclosed |
| US-20230330097-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| EP-3785697-A1 | COSMETIC COMPOSITIONS COMPRISING PIPERLONGUMINE | Unilever N.V. (NL) | 2021-03-03 | — | — | EP | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3368025-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | Fundación Universidad Católica de Valencia San Vicente Mártir (ES) | 2018-09-05 | — | — | EP | disclosed |
| EP-3177144-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | Bioventures, LLC. (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2017012774-A1 | COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER | FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR (ES) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016014625-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY DEPLETING SENESCENT CELLS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20150359888-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | PALO ALTO INVESTORS | 2015-12-17 | — | — | US | disclosed |
| US-8968755-B2 | Topical base and active agent-containing compositions, and methods for improving and treating skin | SCHLESSINGER JOEL (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | SCHLESSINGER JOEL (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2561868-A1 | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field | Van Oosten, Anton Bernhard (BE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2550063-A1 | ALR2 INHIBITORS AND THEIR SYNTHESIS FROM A NATURAL SOURCE | Council of Scientific & Industrial Research (IN) | 2013-01-30 | — | — | EP | disclosed |
| US-20120245357-A1 | ALR2 INHIBITORS AND THEIR SYNTHESIS FROM A NATURAL SOURCE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-09-27 | — | — | US | disclosed |
| WO-2011117706-A1 | ALR2 INHIBITORS AND THEIR SYNTHESIS FROM A NATURAL SOURCE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177618-A1 | TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN | FANCI, FANCF, FANCD2 | ALDH1A1 3934/4885TP53 1995/4885HSD17B10 3055/4885 |
| US-20230330097-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | EPDR1, HYOU1, MYOC | ALDH1A1 186/4885TP53 739/4885HSD17B10 3316/4885 |
| US-12070465-B2 | Compositions and methods for the prevention and treatment of hearing loss | EPDR1, HYOU1, MYOC | ALDH1A1 218/4885TP53 666/4885HSD17B10 3465/4885 |
| US-20120245357-A1 | ALR2 INHIBITORS AND THEIR SYNTHESIS FROM A NATURAL SOURCE | INSRR, AGTR2, ERG28 | ALDH1A1 3080/4885TP53 3094/4885HSD17B10 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.